Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Mar
10
Today In Oncology
Stanford Names Leader for Drug Development and Precision Oncology
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks
FDA Releases Updated Guidance on Biosimilar Development
SABCS 2025: High-Level Review of Select Data
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo